Lates News

According to Economic Daily News, Donghai Securities released a research report on August 25th, giving a buy rating to JF Biotech (688278.SH). The rating reasons mainly include: 1) the company's performance continues to grow rapidly; 2) Pazopanib continues to increase in volume, deepening the clinical cure of hepatitis B; 3) Long-acting growth hormone has been approved for listing, actively expanding new technology platforms.